BCDA BioCardia, Inc.

Nasdaq biocardia.com


$ 1.26 $ -0.04 (-3.08 %)    

Thursday, 13-Nov-2025 15:55:50 EST
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 1.26
$ 1.29
$ 1.25 x 6
$ 1.39 x 2
-- - --
$ 1.00 - $ 3.20
57,686
na
13.37M
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-26-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 03-27-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-29-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-29-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-30-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-15-2020 03-31-2020 10-Q
24 04-09-2020 12-31-2019 10-K
25 11-19-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-15-2019 03-31-2019 10-Q
28 04-02-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-16-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-11-2017 03-31-2017 10-Q
36 03-30-2017 12-31-2016 10-K
37 10-17-2016 09-30-2016 10-Q
38 08-02-2016 06-30-2016 10-Q
39 05-03-2016 03-31-2016 10-Q
40 03-25-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biocardia-q3-eps-024-beats-025-estimate

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by ...

 earnings-outlook-for-biocardia
Earnings Outlook For BioCardia
11/11/2025 18:03:22

 biocardia-updates-atm-offering-raising-maximum-aggregate-sale-to-5309253

This prospectus supplement updates and amends certain information in our base prospectus, dated December 5, 2023, as supplement...

 biocardia-regains-compliance-with-nasdaq-listing-requirements

BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pu...

 hc-wainwright--co-reiterates-buy-on-biocardia-maintains-25-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy and maintains $25 price target.

 biocardia-prices-public-offering-of-48m-shares-and-warrants-at-a-combined-price-of-125-for-up-to-12m-in-gross-proceeds

BioCardia®, Inc. (NASDAQ:BCDA) ("BioCardia" or the "Company"), a developer of cellular and cell-derived therape...

 biocardia-announces-primary-endpoint-results-of-open-label-roll-in-cohort-of-cardiamp-cell-therapy-in-chronic-myocardial-ischemia-trial

BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pu...

 biocardia-inc-files-for-offering-of-up-to-28m-shares-of-common-stock-together-with-up-to-28m-common-warrants

- SEC Filing

 biocardia-q2-eps-040-beats-050-estimate

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.50) by ...

 biocardia-provides-expected-timing-for-regulatory-activities-for-fda-and-japan-pmda-approvals-of-its-cardiamp-cell-therapy-system-and-helix-transendocardial-delivery-catheter

Q3 2025 Helix application for approval to FDAThe Company intends to submit for approval of the Helix Transendocardial Delivery ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION